Atrofi ve proksimal kas güçsüzlüğü olan olgu: seronegatif Lambert Eaton Myastenik Sendrom

Year 2019, , 181 - 183, 18.01.2019

Bahar Say , Ufuk Ergün , Gülten Karaca

https://doi.org/10.31362/patd.453646

Abstract

Lambert
Eaton Myastenik Sendrom (LEMS) proksimal kas güçsüzlüğü, reflekslerde azalma
veya kayıp, ılımlı oküler bulgular ve otonom bulgular ile seyreden presinaptik
voltaj bağımlı kalsiyum kanallarına antikor gelişimi ile karekterize nadir
görülen nöromuskuler kavşak hastalığıdır. Paraneoplastik veya otoimmün
olabilir. Paraneoplastik LEMS en sık küçük hücreli akciğer kanseri ile
birliktelik gösterir. Primer otoimmun olarak ise diyabet, romatoid artrit,
sistemik lupus eritematozus, otoimmun tiroid hastalıklarıyla birliktelik
gösterebilir. Tanı klinik bulgular ve elektrofizyolojik olarak ardışık sinir
uyarım testi veya tek lif elektromyelografi ile konur. Tedavisinde olguya göre
3,4 diaminopiridin, ıntravenöz immunglobulin, plazmaferez, prednizolon ve
azotiopürin yer alır.

Keywords

proksimal kas güçsüzlüğü, otonom bulgular, Lambert Eaton Myastenik Sendromu

Case with atrophy and proximal muscle weakness: seronegative Lambert Eaton Myasthenic Syndrome

Abstract

Abstract

Lambert
Eaton Myasthenic Syndrome (LEMS) is a rare neuromuscular junction disease
characterized by proximal muscle weakness, decrease or loss of reflexes, moderate
ocular and autonomic findings with antibody development to presynaptic
voltage-dependent calcium channels. It can be paraneoplastic or autoimmun. Paraneoplastic
LEMS is most commonly associated with small-cell lung cancer. Primary autoimmune
may be associated with diabetes, rheumatoid arthritis, systemic lupus
erythematosus, autoimmune thyroid diseases. Diagnosis is based clinical
findings and electrophsyologic studies include repetetif nerve stimulation or
single fiber electromyelography. Treatment includes 3,4 diaminopyridine,
intravenous immunglobulin, plasmapheresis, prednisolone and azothiopurine
according to the case.

Keywords

proximal muscle weakness, autonomic findings, Lambert Eaton Myasthenic Syndrome

References

• Referans1. Schoser B, Eymard B, Datt J, Mantegazza R. Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer. J Neurol 2017;264(9):1854-1863.
• Referans2. Eaton LM, Lambert HT. Electromyography and electrical stimulation of nerves in disease of the motor ünit: observations on a myastenic syndrome associated with malignant tumours. J Amm Med Assoc 1957;163:117-1124.
• Referans3. Kesner VG, Oh SJ, Dimachkie MM, Barohn RJ. Lambert eaton myasthenic syndrome. Neurol Clin 2018;36: 379–394.
• Referans4. Crone C, Christiansen I, Vissing J. Myopathic EMG findings and type II muscle fiber atrophy in patients with Lambert-Eaton myasthenic syndrome. Clin Neurophysiol 2013;124(9):1889-1892.
• Referans5. Komatsu T, Bokuda K, Shimizu T, Komori T, Koide R. Pseudomyopathic changes in needle electromyography in lambert-eaton myasthenic syndrome. Case Rep Neurol Med 2013;369278.
• Referans6. Gökçal E, Gürsoy AE, Asil T, Ertaş M. Lambert-Eaton Myasthenic Syndrome with a twenty-three-year delay in diagnosis. Noro Psikiyatr Ars 2017;54(2):189-190.
• Referans7. Oh SJ, Hatanaka Y,Claussen GC, Sher E. Electrophysiological differences in seropositive and seronegative Lambert-Eaton myasthenic syndrome. Muscle Nerve 2007;35(2):178-183.
• Referans8. Zalewski NL, Lennon VA, Lachance DH, Klein CJ, Pittock SJ, Mckeon A. P/Q- and N-type calcium-channel antibodies: oncological, neurological, and serological accompaniments. Muscle Nerve 2016;54(2):220-227.